FluoGuide A/S informed that the presentation of the results from the clinical trial of FG001 used to guide surgery in patients with aggressive high-grade glioma brain cancer. As a follow-up on the award-winning presentation done by Principal Investigator and Chief Surgeon Jane Skjøth-Rasmussen at the 68th Scandinavian Neurosurgical Society (SNS) Congress held 14-16 May 2022, in Bergen, Norway, FluoGuide held a company presentation on the 17 May 2022 where Chief Surgeon Jane Skjøth-Rasmussen, did a presentation of the same data that will be presented at the SNS congress follow up by comments from the FluoGuide management.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.9 SEK | +7.47% | +9.27% | -20.10% |
Mar. 20 | FluoGuide A/S Approves Board Changes | CI |
Mar. 12 | FluoGuide A/S Enters Collaboration Within Robot Assisted Head and Neck Cancer Surgery with Intuitive Surgical, Inc | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.10% | 50.89M | |
+8.07% | 218B | |
+6.59% | 182B | |
+11.26% | 132B | |
+26.57% | 108B | |
+13.35% | 52.98B | |
-0.62% | 47.59B | |
-0.93% | 39.96B | |
+11.54% | 39.22B | |
+26.76% | 26.94B |
- Stock Market
- Equities
- FLUO Stock
- News FluoGuide A/S
- FluoGuide Publish the Presentation of FG001 Results from the First Clinical Trial in Aggressive Brain Cancer